Medicine and Dentistry
Drug-Eluting Stent
100%
Health Care Cost
74%
Odds Ratio
68%
Percutaneous Coronary Intervention
64%
Cost-Effectiveness Analysis
57%
Kidney Function
47%
Chronic Kidney Disease
47%
Uric Acid
47%
Medical Device
47%
Consumer
47%
Anticoagulant
47%
Congestive Heart Failure
47%
BRCA1
47%
Hypoparathyroidism
47%
Mastectomy
47%
Direct Oral Anticoagulant
47%
Salpingooophorectomy
39%
Edoxaban
35%
Isotopes of Calcium
23%
Doppler Echocardiography
23%
Left Ventricle
23%
Myocardial Disease
23%
Drug Therapy
23%
Coronary Artery
23%
Anesthesiology
23%
Antithrombotic
23%
Rivaroxaban
23%
Heart Muscle Biopsy
23%
Two Dimensional Echocardiography
23%
Morphology
23%
Apixaban
23%
Endoplasmic reticulum
23%
Cardiac Catheterization
23%
Glomerular Filtration Rate
23%
Rapamycin
17%
Logistic Regression Analysis
17%
Endovascular Aneurysm Repair
15%
Medical Economics
11%
Atrial Fibrillation
11%
Cardiology
11%
BRCA2
11%
Dabigatran
11%
Anesthetic Agent
11%
Warfarin
11%
Everolimus
11%
Percutaneous Aortic Valve Replacement
10%
Health Technology
10%
Technology Assessment
10%
Hyperuricemia
9%
Ovarian Cancer
7%
Keyphrases
Heart Failure
47%
Perception Gap
47%
Medical Information Service
47%
Hospital Services
47%
Medical Office
47%
Loyalty
47%
Office System
47%
Organizational Commitment
47%
Primary Hypoparathyroidism
47%
Innovation Creation
47%
Wastage
47%
Sickness Absence
47%
Perfect Competition
47%
Reimbursement Costs
47%
Medical Device Market
47%
Medical Perception
47%
Organizational Environment
31%
Coping Ability
31%
Sense of Coherence
31%
Non-affiliated
26%
Cardiac Catheterization
23%
Metabolic Changes
23%
Left Ventricle
23%
Endoplasmic Reticulum
23%
Cardiac muscle
23%
Valvular Disease
23%
Doppler Echocardiography
23%
Serum Calcium
23%
Two-dimensional Echocardiography
23%
Normal Coronary Arteries
23%
Dilatation
23%
Muscle Biopsy
23%
Hospital Administrators
23%
Myocardial Disease
23%
Hospital Selection
23%
Medical Representative
23%
Morphological Changes
23%
Volume Operator
21%
Health Organizations
15%
Job Stress Factors
15%
Nursing Performance
15%
Risk Environment
15%
Differences in Perception
11%
Medical Methods
11%
Two-tier
11%
Permissible Range
11%
Anesthetic Drugs
11%
New Indication
11%
Medication Schedule
11%
Conjoint Analysis
8%
Pharmacology, Toxicology and Pharmaceutical Science
Vascular Disease
47%
Anesthetic Agent
47%
Chronic Kidney Failure
47%
Aneurysm
47%
Heart Disease
47%
Ovary Cancer
47%
Cardiovascular Disease
47%
Breast Cancer
47%
Uric Acid
47%
Anticoagulant Agent
47%
Direct Oral Anticoagulant
47%
Edoxaban
35%
Rivaroxaban
23%
Apixaban
23%
Adverse Event
23%
Hormone Cancer Therapy
23%
Chemotherapy
23%
Cancer Incidence
23%
Malignant Neoplasm
23%
Mortality Rate
23%
Warfarin
11%
Atrial Fibrillation
11%
Dabigatran
11%
Hyperuricemia
9%